Wells Fargo & Company Sarepta Therapeutics, Inc. Put Options Transaction History

Wells Fargo & Company

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2023 Nov 13, 2023	BUY	$102.5 - $123.59 $4.73 Million - $5.7 Million	46,100 Added 517.98%	55,000 $6.67 Million
Q4 2022 Feb 13, 2023	BUY	$100.86 - $132.13 $897,654 - $1.18 Million	8,900 New	8,900 $1.15 Million
Q1 2021 May 13, 2021	SELL	$72.25 - $168.95 $447,950 - $1.05 Million	-6,200 Reduced 31.31%	13,600 $1.01 Million
Q4 2020 Feb 09, 2021	BUY	$125.56 - $178.74 $1.34 Million - $1.91 Million	10,700 Added 117.58%	19,800 $436,000
Q3 2020 Nov 05, 2020	BUY	$127.12 - $172.34 $1.16 Million - $1.57 Million	9,100 New	9,100 $264,000

530

84.5M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $11.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.